Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

"I am excited to join Galapagos at this pivotal moment,” said Aaron Cox, incoming CFO of Galapagos. "I look forward to working with Henry and the talented team to help shape the company's next chapter ...

Q4 2025 Management View President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five ...

The cystinosis treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough th ...

Over the last 7 days, the United States market has risen by 1.2%, and over the past year, it has climbed by 11%, with earnings forecasted to grow annually by 14%. In this context of growth, ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, ...

Six months after Amgen closed its nearly $28 billion acquisition of Horizon Therapeutics, the pharma giant is banking on the rare disease pipeline scored in the deal to buoy its long-term growth. In a ...

Prior to the U.S. Federal Trade Commission's challenge to Amgen's $27.8 billion attempt to acquire Horizon Therapeutics, it had been more than a decade since the agency had challenged a merger in ...

Amgen’s $28 billion deal to acquire Horizon Therapeutics has hit a regulatory obstacle. ... California-based pharma giant framed Horizon’s product portfolio and pipeline as complementary to ...

The acquisition, announced in December, was seen as another move by a large pharma company to build out its rare disease pipeline. Horizon’s Tepezza, a treatment approved by the Food and Drug ...

Horizon Therapeutics stock jumped up on the news that the company is in talks to be bought out. The stock closed at $78.76 and opened the next day at $102.65, a 30% gain.